Bleeding

P-001 Molecular genetic investigations in Hereditary Hemorrhagic Telangiectasia in Hungary; identification of a founder mutation
Réka Gindele, Hungary

P-002 Risk of minor and major bleeding in patients who switched from vitamin K antagonists to direct oral anticoagulants
Myrthe Toorop, The Netherlands

P-003 Reversal of apixaban anticoagulation by andexanet alfa in healthy subjects: a subgroup analysis of the reversal activity using an optimized anti-FXa activity assay vs commercial anti-FXa assays
Genmin Lu, United States

P-004 The influence of glomerular filtration rate on bleeding and mortality risk during hospitalization – multi center cohort
Sonja Salinger, Serbia

P-005 DOAC Filter®: a useful tool to monitor unfractionated heparin anti-Xa activity after periprocedural interruption of anti-Xa direct oral anticoagulants
Nicolas Gendron, France

P-006 Living Well with Haemophilia: The everyday experience of haemophilia in Europe in 2018
Camillo de Vivanco, Denmark

P-007 The impact of specimen volume and haemolysis on routine coagulation test results: reducing the recollection burden in a high-throughput laboratory
Rebecca Toole, New Zealand

P-008 A new fully automated FXIII activity assay.
Nikolaus Binder, Austria

P-009 Dosage of factor IX in persons with Hemophilia B treated with recombinant FIX linked to an IgG Fc domain: Comparison of 3 methods in a French hospital
Andreas Perrier-Comet, France

P-010 Evaluation of a new extraction thromboplastin reagent with ISI close to 1.0 for the measurement of prothrombin time, international normalized ratio and factor assays.
Jonathan Douxfils, Belgium

P-011 Importance of classification and genetic tests in the diagnosis and differential diagnosis of von Willebrand disease type 2N
Adrienne Kerényi, Hungary

P-012 Developing an Assay for Anti-Emicizumab Antibodies in Patients with Haemophilia A
Tanya Fahmy, United Kingdom

P-013 Evaluation of the analytical performances of new apixaban & rivaroxaban low range anti-FXa activity assays on STA-R & STA-Compact Max after reversal by andexanet alpha
Matthieu Bourdin, France

P-014 Acquired FXIII deficiency due to anti-FXIII-A autoantibody; unusual laboratory and clinical characteristics
László Muszbek, Hungary
P-015  Outcome of major haemorrhage in a tertiary cardiothoracic centre in patients with activated major haemorrhage protocol vs non-activated protocol.
Kathryn Chang, United Kingdom

P-016  Gastrointestinal bleeding in patients with bleeding disorders
Bronwen Johns, United Kingdom

P-017  Adaptation and comparison of the technical performance of two chromogenic FVIII assay reagents
Claire Flaujac, France

P-018  Frequency of large deletions and duplications of F8 gene in hemophilia A patients from Serbia
Nina Ilic, Serbia

P-019  Management of cardiovascular patients with hemorrhoidal bleeding under antiplatelet or anticoagulant therapy
Aleksandra Tsitskarava, Russia

P-020  Chromogenic Factor VIII in Haemophilia A plasma of patients with emicizumab
Nikolaus Binder, Austria

P-021  Case study: Laboratory experience of severe Haemophilia A inhibitor patients treated with Emicizumab
Jane Needham, United Kingdom

P-022  Calibrated automated thrombogram values in pediatric craniosynostosis surgery
Saskia Luijnenburg, The Netherlands

P-023  A multicenter experience with idarucizumab “in real world” as reversal anticoagulation of dabigatran
Irene Amarilla Lanzas, Spain

P-024  Correlation of the parameters of thromboelastogram with the results of coagulation tests in hemophilia A patients with prophylaxis
Valeriia Krasivska, Ukraine

P-025  A new fully automated ADAMTS-13 activity assay.
Nikolaus Binder, Austria

P-026  Investigating a potential new bleeding mechanism through novel, atypical GPIb-IX-V receptor complex mutants
Jack Yule, United Kingdom

P-027  Rare bleeding disorders in southern Iran: revisited and updated data
Mehran Karimi, Iran

P-028  Treatment with recombinant Von Willebrand factor (VWF) in type 2 Von Willebrand patient for a total knee replacement (TKR) and comparison with a precedent TKR with plasma-derived VWF concentrate
Claire Flaujac, France

P-029  Unexplainable acute bleeding due to acquired factor XIII deficiency induced hyperfibrinolysis in patients with chronic phase of chronic myeloid leukaemia– three case reports
Bhaddika Jayaratne, Sri Lanka

P-030  Inhibitor against coagulation Factor XIII: A case report
Mehran Karimi, Iran
P-031 Systematic review of the risk of bleeding in patients with renal insufficiency treated with tinzaparin.  
Esteve Colome, Spain

P-032 Perioperative management of patients with rare bleeding disorders  
Carlos Francisco Hernández Mata, Spain

P-033 Desmopressin for reversal of Antiplatelet drugs in Stroke due to Haemorrhage (DASH): rationale and design of a phase II double blind randomised controlled trial  
Michael Desborough, United Kingdom

P-034 Management of anticoagulant therapy in pacemaker implantation, retrospective study in an intensive care unit.  
Pablo Romero Garcia, Spain

P-035 An unusual presentation of Clopidogrel side effects  
Jurgita Janukonyte, Denmark

P-037 Subgaleal hematoma in infant with severe hemophilia A  
Ankica Jovanovic, Serbia

P-038 Thrombosis in haemophilia – how could it happen?  
Lucia Stanciakova, Slovakia

P-039 Thrombotic complications and bleeding disorders of haemostasis  
Lucia Stanciakova, Slovakia

Clotting

P-040 The risk of a first venous thrombosis associated with elevated D-dimer and thrombin generation in elderly  
Huijie Wang, The Netherlands

P-041 Hypertension is associated with lower risk of venous thromboembolism in men  
Magdalena Johansson, Sweden

P-042 The association of a procoagulant state with venous thrombosis in patients with lower-leg injury  
Carolina Touw, The Netherlands

P-043 Is the Caprini score a useful tool to predict venous thrombosis in orthopedic patients?  
Carolina Touw, The Netherlands

P-044 Coagulation factor V is associated with immune response and tumor lymphocyte recruitment in breast cancer  
Mari Tinholt, Norway

P-046 Safety of rivaroxaban in the diagnostic work-up of deep vein thrombosis  
Synne Fronas, Norway

P-047 Tissue factor is constrained by interaction with the pdz-1 domain of magi-1 protein  
Mohammad Mohammad, United Kingdom

P-048 Kidney injury can be a predictor of intrahospital mortality and fatal bleeding in patients with acute pulmonary embolism  
Boris Dzudovic, Serbia
P-049 Plasma levels of leptin and future risk of incident venous thromboembolism
Vania Morelli, Norway

P-050 Pregnancy-related venous thromboembolism risk in women from families with thrombophilia: results from the MARseilles FAmily Study on venous Thrombosis (MARFAST)
Pierre Suchon, France

P-051 Transfusion requirements in adult patients with paroxysmal nocturnal hemoglobinuria naive to complement inhibitors receiving ravulizumab and eculizumab: results from a phase 3 non-inferiority study
Talha Munir, United States

P-052 Prevalence and incidence of venous thromboembolism in Norway 2010 – 2017
Waleed Ghanima, United Kingdom

P-053 Efficacy and safety of the long-acting complement C5 inhibitor ravulizumab in adult patients with atypical haemolytic uraemic syndrome (aHUS)
Marie Scully, United Kingdom

P-054 Hidden antithrombin variant detected by whole genome sequencing that modulates the N-glycosylation efficacy. Clinical implications and basic mechanisms.
María Eugenia De La Morena-Barrio, Spain

P-055 Recurrence risk of transient inflammation-associated venous thromboembolism: similar to provoked, unprovoked or in-between?
Soerajja Bhoelan, The Netherlands

P-056 Patients with high post-endovascular treatment plasma levels of neutrophil activation markers are at higher risk of poor functional outcome, HT, and mortality.
Lucas Di Meglio, France

P-057 Plasma levels of complement component C5 are associated with future risk of incident venous thromboembolism
Espen Waage Skjeflo, Norway

P-058 Detection of pulmonary embolism in exhaled breath condensate - a porcine model
Inger Lise Gade, Denmark

P-059 The pharmacokinetics and pharmacodynamics of nadroparin in children with venous thromboembolism
Marit Boerma, The Netherlands

P-060 Comparison of coagulation properties of microparticles derived from platelets, erythrocytes, leukocytes and endothelial cells
Alexey Mazurov, Russia

P-061 Inhibitor effects on clot growth: different profiles of inhibition.
Cornelis Kluit, The Netherlands

P-062 Alpha2-plasmin inhibitor and its C-terminal proteolytic variation in venous thrombosis
Éva Katona, Hungary

P-063 Rosuvastatin use reduces the procoagulant phospholipid (PPL) activity in patients with venous thromboembolism: a randomized controlled trial
John-Bjarne Hansen, Norway

P-064 Replacement of pt-inr monitoring of warfarin with fix-nr reduces thromboembolism, anticoagulation variability, testing frequency and dose adjustment need without raising time in
The Value of Neuroimaging and Implications for Long-term Neurological Sequelae of Thrombotic Thrombocytopenic Purpura: A Tertiary Centre Experience
Rebecca Jane Shaw, United Kingdom

Limitations of the Villalta scale in diagnosing the post-thrombotic syndrome
Marit Engeseth, Norway

Characterisation of a novel genetically modified fxiii-a I34v model shows altered thromboembolism dynamics
Adomas Baranauskas, United Kingdom

The risk of deep vein thrombosis and pulmonary embolism attributed to recognized prothrombotic genotypes
Sigrid Brække, Norway

Anticoagulant treatment duration and risk of recurrent venous thromboembolism: an instrumental variable analysis from the MEGA follow-up study
Fleur van Velthoven, The Netherlands

Unraveling the molecular mechanism of tick protein BSAP1, a putative extrinsic coagulation pathway inhibitor
Stepan Denisov, The Netherlands

Additive effect of oxygen saturation and chronic obstructive pulmonary disease on the risk of incident venous thromboembolism
John-Bjarne Hansen, Norway

The LumiraDx Platform INR test: Performance and ease of use in an anticoagulation clinic setting
Jayne Ellis, United Kingdom

Thrombin generation in patients with lower-leg injury
Carolina Touw, The Netherlands

Identification of a circulating lipid profile associated with venous thromboembolism
Álvaro Fernández-Pardo, Spain

The role of bacterial proteases in prothrombin activation
Vincenzo De Filippis, Italy

Role of factor VIII and von Willebrand factor in the relation between risk of venous thrombosis and their risk factors
Filippo Castelli, Italy

MicroRNA-494 upregulates TFPI-2 expression in MCF-7 breast cancer cells
Marianne Andresen, Norway

Hospital-based Diagnoses of Low Back Pain and Risk of Myocardial Infarction, Stroke, and Venous Thromboembolism
Emil Zåi Riahi, Denmark

Dabigatran Therapy Provides Better Inhibition Against Intracardiac Activation of Hemostasis as Compared to Vitamin K Antagonists During Cryoballoon Catheter Ablation of Atrial Fibrillation
Zsuzsa Bagoly, Hungary
Early mortality risk is associated with prolonged clot lysis time in acute pulmonary embolism: contribution of NETosis
Michał Żabczyk, Poland

In-depth epitope mapping of anti-ADAMTS13 autoantibodies in immune-mediated thrombotic thrombocytopenic purpura patients using a large library of ADAMTS13 fragments
Katri Kangro, Belgium

High plasma levels of mannose-binding lectin are associated with non-O blood type and increased risk of venous thromboembolism
Robin Amanda Liang, Norway

Exploring a novel interaction between the intrinsic pathway of coagulation and complement
Samantha Heal, United Kingdom

Plasmatic protein C levels are determined by genetic variants in the promoter and the intron 2 of the protein C gene
Álvaro Fernández-Pardo, Spain

Plasma P-selectin as Predictive Biomarker for Incident Venous Thromboembolism in Women
Tine Hiorth Schøyen, Norway

Decadal results from a single centre cohort: Maternal and fetal outcomes in women with antiphospholipid antibodies
Karen Schreiber, United Kingdom

Novel thermostable inhibitor of contact activation TICA effectively blocks contact activation in low tissue factor thrombin generation.
Tom van de Berg, The Netherlands

Does a meal affect thrombin generation? New insights from the NEO study
Sara Arcudi, Italy

Neutrophil Extracellular Traps Accelerate Clotting and Produce a Denser Clot Structure in Plasma
Yu Shi, United Kingdom

Impaired right ventricular function in patients with chronic thromboembolic disease
Øyvind Jervan, Norway

The ratio of factor VIIa:tissue factor content within microvesicles determines the differential influence on endothelial cells.
Yahya Madkhali, United Kingdom

Pregnancy outcomes in patients with atypical haemolytic uraemic syndrome
Marie Scully, United Kingdom

Characterisation of a novel F5 gene mutation (Ala2086Asp, Factor V Besançon) associated with factor V deficiency and recurrent venous thrombosis
Elisabetta Castoldi, The Netherlands

Design of a “catch and release assay” for circulating FXIIa.
Stan van der Beelen, The Netherlands

Opium as a risk factor for coronary artery disease in young Iranians; results from the premature CAD Milano-Iran (MIran) study
Alberto Maino, Italy
P-099  A validated metabolomic plasma profile associated with venous thromboembolism
Álvaro Fernández-Pardo, Spain

P-101  The impact of age on the pharmacological activity of factor X inhibitors, rivaroxaban and
apixaban
Emmanouela Kampouraki, United Kingdom

P-102  The effects of a peripheral venous catheter compared to repeated venepunctures on markers
of coagulation, inflammation, and endothelial function
Line Espenhain, Denmark

P-103  Discrepant interpretation of HIT screening results on the same sample - data from a UK NEQAS
for Blood Coagulation exercise.
Anna Lowe, United Kingdom

P-104  Molecular genetic investigations in antithrombin deficient children; investigation of genotype-
phenotype relationship
Zsuzsanna Bereczky, Hungary

P-105  New fibrinolytic technology based on serine protease subtilisin
Eugene Roitman, Russia

P-106  The association of antithrombin activity with the risk assessment of acute pulmonary embolism
and predictive significance for 30-day mortality
Boris Dzudovic, Serbia

P-107  Plasma clot formation, lysis, fibrin fiber density and mechanics from patients with acute PE
before and after initial treatment with low molecular weight heparin
Stephen Baker, United Kingdom

P-109  Examination of the interacting domains between the extracellular domains of tissue factor and
β1-integrin and their influence on cell proliferation.
Sophie Featherby, United Kingdom

P-111  Soluble fibroblast activation protein (sFAP) and alpha2-plasmin inhibitor p.Arg6Trp
polymorphism in venous thrombosis
Barbara Baráth, Hungary

P-112  Analysis of the differential expression of miRNAs present in plasma and contained within
microparticles in severe forms of pulmonary hypertension
Julia Oto, Spain

P-113  The effects of acute and chronic exercise on Factor VIII and von Willebrand antigen plasma
levels in well trained athletes
Nikolaos Androulakis, Greece

P-114  Empowering cancer patients for non-pharmacological primary prevention and early
recognition of cancer-associated venous thromboembolism (VTE): the EMPATIC-CP survey.
Carme Font Puig, Spain

P-115  The glycan structure of factor XIII B subunit
Boglárka Hurják, Hungary

P-116  Dietary zinc modulates several haemostatic parameters
Um-May Sumya, United Kingdom

P-117  A phase 3 study of ravulizumab (ALXN1210) vs eculizumab in adults with paroxysmal nocturnal
hemoglobinuria currently treated with eculizumab: subgroup analyses by transfusion history
and demographics
Austin Kulasekararaj, United States

P-118 Prediction and measurement of human PEG plasma levels after administration of PEGylated biologics and their value for safety assessment
Andreas Baumann, Germany

P-119 Global hemostatic assays (OHP and ETP) have no additional value compared to D-dimer in the diagnosis of acute venous thrombosis
Maria Farm, Sweden

P-120 Obtaining renal function results before empiric rivaroxaban in the diagnostic work-up of deep vein thrombosis
Synne Fronas, Norway

P-121 The effect of DOAC-Remove on activated protein C resistance testing in venous thromboembolism patients receiving direct oral anticoagulants
Magdalena Kopytek, Poland

P-122 Clinical outcomes of International Normalized Ratios Measured every 8 Weeks versus 12 Weeks in Venous Thromboembolism Patients with Stable Warfarin Dose: Prospective Cohort study
Fahad Aleidan, Saudi Arabia

P-123 Plasma lipopolysaccharide-binding protein is a biomarker for future deep vein thrombosis in women; results from untargeted discovery and validation studies
Søren Beck Jensen, Norway

P-124 Antiphospholipid antibodies and thrombosis in none BCR-ABL myeloproliferative neoplasms
Ruta Dambrauskiene, Lithuania

P-125 Why do we not investigate suspected deep vein thrombosis according to current guidelines?
Johan Tjällman, Sweden

P-126 An unusual case of abdominal pain
Eleonora Rizzi, Italy

P-127 The effects of Edoxaban on routine coagulation tests
Hazel Medforth, United Kingdom

P-129 The role of red blood cells surface proteins in hemostasis and thrombosis
Karina Vidovic, Sweden

P-130 The FibWave: a new rapid and relevant tool for the evaluation of anticoagulant drugs
Jonathan Evrard, Belgium

P-131 Incidence of prothrombotic risk factors in perinatal stroke onset
Jelena Vukajlovic, Serbia

P-132 Evaluation of the new QXpert Hemostasis Analyzer for routine coagulation tests
Pierre Toulon, France

P-133 Course of fatigue symptoms following initiation of rivaroxaban for the treatment of venous thromboembolism
Waleed Ghanima, Norway

P-134 Impact of duration of anticoagulant therapy on survival and bleeding or thrombotic complications in patients with cancer-associated thrombosis: data from a retrospective cohort
study.
Annalisa Dalla Salda, Italy

P-135 Validation of a model with coagulation-related markers for the diagnosis of periprosthetic joint infection
Julia Oto, Spain

P-136 The therapeutic plasma exchange (TPE) in patients with thrombotic thrombocytopenic purpura (TTP)
Bratislav Stankovic, Serbia

P-137 D-dimer as a stand-alone test to rule out deep vein thrombosis
Fridtjof Rinde, Norway

P-138 Less is more: Reduced anticoagulation therapy in patients after mechanical aortic On-X valve replacement in real life. Experience of a Spanish single centre.
Jose Agustín Rodríguez-Alén, Spain

P-139 Plasma level of complement factor B is associated with risk of future venous thromboembolism
Søren Beck Jensen, Norway

P-140 Plasma Von Willebrand Factor (VWF) and ADAMTS13 profiles in patients with Antiphospholipid syndrome (APS) and Systemic lupus erythematosus (SLE)
My Nhi Dang, United Kingdom

P-141 Even if new scores enhance D-dimer testing relevance, D-dimer testing will still be limited if not combined with an appropriate clinical score
Poenou Geraldine, France

P-142 Plasma circulating free DNA levels and DNase I activity are associated to an increased risk of venous thromboembolism
Julia Oto, Spain

P-143 Profile of thrombin generation in children using low tissue factor picomolar concentration with and without thrombomodulin
Susanna Gassiot, Spain

P-144 Current approach to antithrombotic therapy in patient with acute myocardial infarction in pregnancy
Nebojsa Antonijevic, Serbia

P-145 The role of thrombotic risk factors in the aspect of pregnant women anemia correction
Lidiya Buzyan, Russia

P-146 The mechanism of coagulating action of positively charged polyamidoamine dendrimers of low generation
Liliya Mukhametova, Russia

P-147 Lot Specific differences in POC INR testing: UK NEQAS BC investigation
Dianne Kitchen, United Kingdom

P-148 Altered coagulation status in the pathogenesis of Buruli ulcer
Louise Tzung-Harn Hsieh, United Kingdom

P-149 Cerebral Venous Sinus Thrombosis as First Manifestation of Behçet’s Disease
Maria Mylona, Greece
patient preferences for the treatment of paroxysmal nocturnal hemoglobinuria: results of a patient survey of ravulizumab (ALXN1210) and eculizumab in the UK
Ioannis Tomazos, United States

Patient’s preferences for decision-making in anticoagulation: Beyond the clinical criteria
Olga Gavín, Spain

Evaluation of the challenges in the diagnostic methods for the detection of lupus anticoagulant in a third level hospital.
Sergio Pinzón, Spain

Recurrence of VTE in the long-term period: a perspective study
Giacomo Turatti, Italy

Argatroban for therapeutic anticoagulation in two patients with acute thrombosis and heparin resistance
Irina Mindlina, United Kingdom

Reference intervals of routine coagulation tests in healthy term-pregnant Greek women
Eleni Vagdatli, Greece

Evaluation of EQA material on Yumizen G 200 – coagulation analyser: UK NEQAS for Blood Coagulation study.
Liia Brown, United Kingdom

Fibrinogen structure and function under oxidative stress condition
Jana Stikarova, Czech Republic

In vitro determination of the amount of in vivo formed active thrombin in cohorts of patients with various diagnosis
Jan Dyr, Czech Republic

Plasma fractionation: conventional and chromatographic method for factor VIII purification
Natalia Shurko, Ukraine

A case of slow resolution upper extremity DVT
Alice Pirovano, Italy

Management of the repeated thrombotic complications and antithrombin deficiency
Lucia Stanciakova, Slovakia

Risky pregnancy and anticoagulant prophylaxis of the thromboembolic events
Lucia Stanciakova, Slovakia

Is CHA2DS2-VASC Score Useful in Patients with Low Thromboembolic Risk? A Case Report.
Veronica Vassia, Italy

Comparison of prothrombin time (INR) results and main characteristics of patients on warfarin treatment in primary health care centers and anticoagulation clinics
Naser Shagerdi Esmaili, Iran

cavernous sinus thrombosis in AML m3 case under treatment with ATRA
Mehrdad Payandeh, Iran
**Platelets**

P-167  Contribution of the mRNA binding protein CPEB4 in platelet biology through translational control.
  Pablo García De Frutos, Spain

P-168  Exposure of platelet-derived FXIII-A on the activated membrane is dependent on αIIβ3 and intracellular signalling via caspases and Src family kinases
  Fahad Alshehri, United Kingdom

P-169  Dimeric GPVI interacts with the D/aC-region of fibrinogen
  Rui-Gang Xu, United Kingdom

P-170  Platelet sialylation as a new biomarker of immature platelets
  Alexandre Kauskot, France

P-171  Platelet PN-1 regulates clot structure and retraction
  Stephane Loyau, France

P-172  Study of Aspirin and Clopidogrel Resistance by Light Transmittance Aggregometry and Its Association with Adverse Outcomes in Indian Stable Coronary Artery Disease Patients
  Nirmal Ghati, India

P-173  Disagregin: a possible new αIIβ3 integrin inhibitor to prevent arterial thrombosis
  Danique van den Kerkhof, The Netherlands

P-174  Coagulation factor XIII in platelet microparticles formed by receptor mediated and non-receptor mediated platelet activation
  Laura Somodi, Hungary

P-175  Non-psychoactive phytocannabinoids inhibit platelet activation and thrombus formation
  Eman Alzahrani, United Kingdom

P-176  Dasatinib attenuates thrombin generation and clot retraction of convulxin activated human platelets
  Ildikó Beke Debreceni, Hungary

P-177  A shear flow-based assay to assess rituximab prophylaxis in acquired Thrombotic Thrombocytopenic Purpura
  Marie Scully, United Kingdom

P-178  IV abciximab used as a rescue therapy for instant reocclusions during endovascular therapy for acute ischemic stroke
  Jean-Philippe Desilles, France

P-179  Intracellular zinc stimulates reactive oxygen species generation and modifies antioxidant system in platelets
  Maria Lopes-Pires, United Kingdom

P-180  Correlation of Glycated Hemoglobin with Platelet Indices
  Eleni Vagdatli, Greece

P-181  Predictors of contrast-induced nephropathy in patients with ACS after percutaneous coronary intervention
  Aisulu Zhunuspekova, Kazakhstan
P-182 Developing mouse models to investigate the mechanism of SLFN14 mutations in inherited thrombocytopenia
Rachel Stapley, United Kingdom

P-183 Response to antiplatelet therapy measured by multiplate impedance aggregometry and bleeding complications in bypass cardiac surgery patients
Tina Novakovic, Serbia

P-184 The features of acquired thrombotic thrombocytopenic purpura occurring at advanced age
Pasquale Agosti, Italy

P-185 Effect of Thrombopoietin Receptor Agonists (TPO-RAs) on Neutrophil Extracellular Trap (NET) Formation in Immune Thrombocytopenia (ITP)
Lamya Garaebt, Norway

P-186 Influence of the P2Y12 receptor inhibitor action in patients with coronary heart disease after implantation of DES stents in view of CYP2C19 gene polymorphisms
Jamol Uzokov, Uzbekistan

P-187 Platelets in the uremic milieu: Exploring the link between protein carbamylation and platelet dysfunction in ESRD
Veronika Binder, Norway

P-188 Adenosine receptor agonists exhibit antiplatelet effect and ability to overcome P2Y12 receptor antagonists drug resistance
Nina Wolska, Poland

P-189 Statins potentiate the antibacterial effect of platelets on Staphylococcus aureus
Laurence Camoin-Jau, France

P-190 Retrospective study on the management of antiplatelet therapy in pacemaker implantation in an intensive care unit
Pablo Romero Garcia, Spain

P-191 Predictive factors for successful splenectomy in children with chronic immune thrombocytopenic purpura - single center experience
Milena Jovic, Serbia

P-192 Effect of eucalyptol (1,8 cineole) on the modulation of platelet function, thrombosis, haemostasis and platelet-mediated inflammation
Kahdr Alatawi, United Kingdom

P-193 Evaluation of DOAC Filter® to neutralize argatroban induced interferences on routine coagulation tests.
Nicolas Gendron, France

P-194 Comparison of platelet functional activity in children and adults
Evgeniya Ponomarenko, Russia

P-195 The prognostic value of CYP2C19 gene polymorphisms in the development of adverse cardiovascular events
Aisulu Zhunuspekova, Kazakhstan

P-196 Novel continuous flow cytometry approach to ITP diagnosis is capable of identifying subtypes of the disease and moving forward its understanding
Maria Sorokina, Russia
P-197 Diagnostic and therapeutic dilemmas in HELLP syndrome
Andreas Perrier-Cornet, France

P-198 Mathematical model of platelet response to collagen-related peptide activation suggests a role for PNX-1 in GPVI-induced platelet activation.
Maria Stepanyan, Russia

P-199 Implementability of automated platelet aggregometry on coagulation analyzers for pediatric population
Susanna Gassiot, Spain

P-200 Strong platelet activation in response to ADP in large platelet aggregates
Andrei Kumar Garzon Dasgupta, Russia

P-201 Correlation of spontaneous platelet aggregation with stent length in patients undergoing percutaneous coronary intervention
Nikolaos Androulakis, Greece

P-202 A role for vitamin D in inter-individual variation in platelet function
Ebtihal Alfatani, Ireland

P-203 Flow cytometry for platelet functional characterization in children with essential thrombocythemia
Dmitrii Polokhov, Russia

P-204 Sticky platelet syndrome in patients with thromboembolic complications
Lucia Stanciakova, Slovakia

P-205 How could pregnancy in women with sticky platelet syndrome be managed?
Lucia Stanciakova, Slovakia

P-206 Long lasting prothrombotic state implied by changes of plasma von Willebrand factor parameters (antigen level, collagen binding activity and multimerisation) after radical prostatectomy
Jolan Harsfalvi, Hungary

P-207 PKC-delta-dependent pathways contribute to the exacerbation of the platelet activity in Crohn’s disease
Younes Zaïd, Morocco

P-208 Filipino cultural beliefs: an input to genetic counselling
Jayrelle Safran, Philippines

Vessel Wall

P-209 Thrombomodulin-bound thrombin induces inflammatory signaling through direct cleavage and activation of protease-activated receptor 2
Dorothea Heuberger, Switzerland

P-210 Endothelial-to-mesenchymal transition in venous thrombosis
Sara Robin, France

P-211 Interaction of coagulation factor XII with the opportunistic pathogen Candida albicans
Maria-Louise Williams, United Kingdom

P-212 Investigating the role of neutrophils and NETs in Staphylococcus aureus endocarditis
Severien Meyers, Belgium
<table>
<thead>
<tr>
<th>P-213</th>
<th>Development of novel imaging tracers of microcalcification for early detection of vulnerable atherosclerotic plaques</th>
<th>Anouk Gentier, Belgium</th>
</tr>
</thead>
<tbody>
<tr>
<td>P-214</td>
<td>Extracellular vesicles from patients with pulmonary arterial hypertension modulate endothelial function and angiogenesis</td>
<td>Avinash Khandagale, Sweden</td>
</tr>
<tr>
<td>P-215</td>
<td>Acute hemorrhagic edema of infancy – is that really a mild, benign disease?</td>
<td>Rasa Medovic, Serbia</td>
</tr>
<tr>
<td>P-216</td>
<td>The antiangiogenic effects of acetylsalicylic acid in patients with polycythemia vera</td>
<td>Eugene Roitman, Russia</td>
</tr>
<tr>
<td>P-217</td>
<td>Endothelial Damage and Hypercoagulable State in Diabetic Patients with Gangrene Diabeticum</td>
<td>Sry Suryani Widjaja, Indonesia</td>
</tr>
</tbody>
</table>